

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the United Nations Environment Programme, the International Labour Organization or the World Health Organization.

Environmental Health Criteria 233

TRANSGENIC ANIMAL MUTAGENICITY ASSAYS

First draft prepared by Drs Ulrich Wahnschaffe, Janet Kielhorn, Annette Bitsch and Inge Mangelsdorf, Fraunhofer Institute of Toxicology and Experimental Medicine, Hanover, Germany

Published under the joint sponsorship of the United Nations Environment Programme, the International Labour Organization and the World Health Organization, and produced within the framework of the Inter-Organization Programme for the Sound Management of Chemicals.



World Health Organization
Geneva, 2006

The **International Programme on Chemical Safety (IPCS)**, established in 1980, is a joint venture of the United Nations Environment Programme (UNEP), the International Labour Organization (ILO) and the World Health Organization (WHO). The overall objectives of the IPCS are to establish the scientific basis for assessment of the risk to human health and the environment from exposure to chemicals, through international peer review processes, as a prerequisite for the promotion of chemical safety, and to provide technical assistance in strengthening national capacities for the sound management of chemicals.

The **Inter-Organization Programme for the Sound Management of Chemicals (IOMC)** was established in 1995 by UNEP, ILO, the Food and Agriculture Organization of the United Nations, WHO, the United Nations Industrial Development Organization, the United Nations Institute for Training and Research and the Organisation for Economic Co-operation and Development (Participating Organizations), following recommendations made by the 1992 UN Conference on Environment and Development to strengthen cooperation and increase coordination in the field of chemical safety. The purpose of the IOMC is to promote coordination of the policies and activities pursued by the Participating Organizations, jointly or separately, to achieve the sound management of chemicals in relation to human health and the environment.

WHO Library Cataloguing-in-Publication Data

Transgenic animal mutagenicity assays.

(Environmental health criteria ; 233)

1.Mutagenicity tests - methods. 2.Mice, Transgenic. 3.Risk assessment.
4.Environmental exposure. I.World Health Organization. II.International Programme on Chemical Safety.

ISBN 92 4 157233 7

(NLM classification: QU 450)

ISBN 978 92 4 157233 7

ISSN 0250-863X

©World Health Organization 2006

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications — whether for sale or for noncommercial distribution — should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This document was technically and linguistically edited by Marla Sheffer, Ottawa, Canada, and printed by Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, Germany.

CONTENTS

ENVIRONMENTAL HEALTH CRITERIA FOR TRANSGENIC ANIMAL MUTAGENICITY ASSAYS

PREAMBLE	x
ACRONYMS AND ABBREVIATIONS	xix
GLOSSARY	xxii
1. SUMMARY	1
PART I: OVERVIEW OF GENOTOXICITY TESTING AND TRANSGENIC ANIMAL MUTAGENICITY SYSTEMS	7
2. OVERVIEW OF GENOTOXICITY TESTING	8
2.1 Gene mutation assays in vivo using endogenous genes	8
2.2 Gene mutation assays in vivo using transgenes	8
3. CONSTRUCTION/PRODUCTION OF TRANSGENIC ANIMALS USING AS EXAMPLES THE <i>LACI</i> AND <i>LACZ</i> MUTATION MODELS	10
3.1 The foreign gene construct	10
3.2 Generation of transgenic animals with shuttle vectors: the transfer method	10
3.3 Strains and species used	12
3.4 Target or reporter genes — the <i>lac</i> operon	12
3.5 Transgene shuttle vectors	13
3.6 Transgenic animal models	14
3.6.1 <i>lacI</i> transgenic model — the Big Blue [®] construct	14
3.6.2 <i>lacZ</i> transgenic mouse model — the Muta TM Mouse construct	15

4. THE TRANSGENIC MUTAGENICITY ASSAY — METHODOLOGY USING AS EXAMPLES <i>LACI</i> AND <i>LACZ</i> MUTATION MODELS	16
4.1 Treatment schemes	16
4.2 Collection of (target) tissues and isolation of DNA	16
4.3 Recovery of the DNA construct of the shuttle vector from the genomic DNA and in vitro packaging	16
4.4 Infection into bacteria and plating	18
4.5 Detection and quantification of mutations	18
4.5.1 Big Blue [®] system	18
4.5.2 Muta [™] Mouse system	19
5. FURTHER TRANSGENIC MUTAGENICITY ASSAYS	21
5.1 <i>lacII</i> assay (Big Blue [®] and Muta [™] Mouse)	21
5.2 <i>gpt</i> delta model	24
5.2.1 <i>gpt</i> delta rodents	24
5.2.2 6-TG selection	24
5.2.3 Spi ⁻ selection	24
5.3 The <i>lacZ</i> plasmid model	26
5.4 Upcoming transgenic models for which no extensive data are available	27
5.4.1 ΦX174 transgenic mouse model	27
5.4.2 λsupF transgenic mouse	28
5.4.3 pKZ1 transgenic recombination model	28
5.4.4 <i>rpsL</i> transgenic mouse model	29
6. PARAMETERS AND CRITERIA FOR VALID EXPERIMENTAL DESIGN	30
6.1 Determinants studied using transgenic mutation assays	30
6.1.1 Types of mutations	30
6.1.2 Overall mutant/mutation frequency	30
6.1.3 Spontaneous mutant frequency	31
6.1.4 Sequence analysis	31
6.2 Criteria for valid experimental design of transgenic mutation assays	32
6.2.1 Selection of the most suitable model	32
6.2.2 Duration of exposure	32
6.2.3 Selection of the dose	33

6.2.4	Post-treatment manifestation time	33
6.2.5	Significance of a negative result	35
6.2.6	Factors to consider when comparing the performance of mutation assays	35
6.2.7	Positive control	36
6.2.8	Sensitivity	36
6.2.9	Statistics	37
6.2.10	Analysis of DNA sequence	37
6.2.11	Use of transgenic assays in the detection of gene mutations in germ cells	38
 PART II: COMPARISON OF THE <i>LACI</i> MODEL AND THE <i>LACZ</i> MODEL WITH CONVENTIONAL TEST SYSTEMS		39
<hr/>		
7.	INTRODUCTION TO PART II	40
7.1	Aim of the comparison and criteria for the selection of data	40
7.2	Choice and limitations of data	41
7.3	Validity of data on transgenic animal mutation assays	42
7.4	Criteria for predictivity of transgenic assays	43
8.	COMPARISON OF THE MUTA™MOUSE AND BIG BLUE® ASSAYS	44
9.	TRANSGENIC ASSAYS — COMPARISON WITH OTHER ASSAYS	46
9.1	The Muta™Mouse assay and the Big Blue® mouse assay versus the mouse bone marrow micronucleus test	46
9.1.1	The mouse bone marrow micronucleus test: principles and procedures	61
9.1.2	Comparison of data from the mouse bone marrow micronucleus test and transgenic mouse test	61
9.1.2.1	Bone marrow	61
9.1.2.2	All organs	63
9.1.3	Predictivity of the transgenic animal mutagenicity assays and the mouse bone marrow micronucleus test for carcinogenicity	63

9.1.4	Comparison of both test systems	66
9.1.5	Conclusions	68
9.2	The Muta™Mouse assay and the Big Blue® mouse or rat assay versus assays using endogenous reporter genes	70
9.2.1	Results in the mouse spot test compared with those from transgenic animals	70
9.2.1.1	Description of the mouse spot test	71
9.2.1.2	Comparison of the mouse spot test with transgenic mouse model systems	71
9.2.1.3	Predictivity of the transgenic animal mutagenicity assays and the mouse spot test for carcinogenicity	78
9.2.1.4	Advantages and disadvantages of both test systems	79
9.2.1.5	Conclusions	80
9.2.2	Transgenic animal mutagenicity assay versus <i>Hprt</i> and other endogenous genes	82
9.2.2.1	Description of endogenous gene animal models	87
9.2.2.2	Comparative studies	89
9.2.2.3	Conclusion	93
9.3	Transgenic animal mutagenicity assays and indirect measure of DNA damage using UDS in vivo assay	94
9.4	Results of transgenic animal mutagenicity assays compared with results of genotoxicity assays in vitro	94
9.4.1	Gene mutation	95
9.4.2	Chromosomal aberration	95
9.4.3	Direct or indirect measure of DNA damage	103
9.4.4	Conclusion	103
10.	TRANSGENIC ASSAYS AND CARCINOGENICITY TESTING	104
10.1	Comparison of target organs in carcinogenicity studies with target organs in transgenic animal mutation assays	104
10.1.1	Pattern of target organs	104
10.1.2	Analysis of the predictivity for the liver as target organ	121
10.1.3	Conclusion	127

10.2	Comparison of results of carcinogenicity studies with results from transgenic animal mutagenicity assays	128
10.2.1	Non-genotoxic carcinogens	139
10.2.2	Validity of data on transgenic animal mutation assays	139
10.2.3	Evaluation of the predictivity for carcinogenicity in mice	140
10.2.4	Conclusion	148
PART III: APPLICATIONS OF TRANSGENIC ANIMAL MUTAGENICITY STUDIES		149
<hr/>		
11.	MUTATION FREQUENCIES AND SEQUENCING DATA AND APPLICATIONS OF THIS INFORMATION IN MECHANISTIC STUDIES	150
11.1	Studies on spontaneous mutant/mutation frequencies (in organs of non-exposed transgenic animals)	150
11.1.1	Sources of spontaneous mutations	150
11.1.2	Spontaneous mutation data: sequence data in organs of non-exposed transgenic animals	151
11.1.3	The frequency and nature of spontaneous mutations versus age in multiple tissues	152
11.2	Examination of fundamental paradigms in genetic toxicology	154
11.2.1	Dose–response relationships	155
11.2.2	Correlation of dose with mutation frequency and carcinogenicity	157
11.2.3	Relationship between DNA adducts, cell proliferation and gene mutations	158
11.3	Studies into the mechanism of action of mutagenicity/carcinogenicity using sequence data	161
11.3.1	Clonal correction and correction for ex vivo mutations	161
11.3.2	Premutagenic lesions	162
11.3.3	Tissue-specific responses	164
11.3.4	Evaluation of genotoxicants that do not appear to interact with DNA	166
11.3.5	Active components of mixtures	166
11.3.6	Active metabolites	166
11.3.7	Investigations into the mechanisms of deletion mutations in vivo	167

11.4 Importance of the transgenic mutation assays for studies other than genetic toxicology	169
PART IV: EVALUATION, CONCLUSIONS AND RECOMMENDATIONS	171
12. EVALUATION OF THE TRANSGENIC ANIMAL MUTAGENICITY ASSAYS BASED ON THIS REVIEW OF THE CURRENT LITERATURE	172
12.1 Features of the assay	172
12.2 Gene mutation assay — implications for testing	172
12.2.1 Reliability of a negative result	173
12.3 Comparison with endogenous genes	174
12.4 Molecular analysis and mechanistic studies	174
12.5 Animal welfare and economy	175
13. CONCLUSIONS	177
14. RECOMMENDATIONS	178
REFERENCES	179
APPENDIX 1: MASTER TABLE	215
APPENDIX 2: THE <i>CII</i> ASSAY IN TRANSGENIC RODENT STUDIES	279
RESUME	287
RESUMEN	293

结束，完整报告链接和二维码如下：

www.yunbaogao.cn/report/index/report?reportId=5_29831

